B.Riley keeps Buy rating for Kymera Therapeutics stock
B.Riley has reiterated a Buy rating and a $155.00 price target for Kymera Therapeutics (KYMR) stock following new data on its oral STAT6 degrader KT-621. The valuation is largely dependent on the results of the BROADEN2 Phase 2b study, expected by late 2026, which needs to show comparable skin clearance to existing treatments with improved itch outcomes. Kymera reported a significant revenue increase in Q2 2026 to $65.00 million, primarily from collaboration agreements, and holds $1.50 billion in cash, projected to fund operations through 2029.
Kymera Therapeutics CEO Nello Mainolfi sells $3.4 million in stock
Nello Mainolfi, CEO of Kymera Therapeutics, sold approximately $3.41 million worth of common stock on October 1, 2026, following the exercise of stock options. The sales, executed under a Rule 10b5-1 trading plan, occurred after the company's stock had surged over 101% in the past year. Mainolfi acquired 30,000 shares by exercising options at $2.08 per share before selling them at prices ranging from $111.44 to $116.12, and now directly holds 666,568 shares.
Trading Systems Reacting to (KYMR) Volatility
The article analyzes Kymera Therapeutics Inc. (NASDAQ: KYMR) volatility, highlighting a weak near and mid-term sentiment contrasting with a positive long-term outlook. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. The analysis points to an exceptional 48.2:1 risk-reward setup, targeting a 13.8% gain against a 0.3% risk.
Kymera Therapeutics CEO Nello Mainolfi sells $3.4 million in stock By Investing.com
Kymera Therapeutics CEO Nello Mainolfi sold approximately $3.41 million worth of company stock on October 1, 2026, following the exercise of stock options. The sale was executed under a Rule 10b5-1 trading plan and occurred after the company's stock surged over 101% in the past year, bringing its market capitalization to $9.1 billion. Mainolfi still holds 666,568 shares and 60,000 stock options after the transaction.
A 30,000-share sale is planned by Kymera Therapeutics (KYMR) officer and director Nello Mainolfi.
Kymera Therapeutics officer and director Nello Mainolfi plans to sell 30,000 common shares of KYMR through UBS Financial Services, Inc., valued at approximately $3,353,700. The shares were acquired via stock option exercise on October 1, 2026, the same date as the approximate sale. This follows previous sales by Mainolfi in July 2026, totaling 130,000 shares with gross proceeds of over $15 million.
Form 4 Kymera Therapeutics Inc For: 1 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Kymera Therapeutics Inc. dated October 1st. It also includes various market data such as indices, commodities, and bonds, alongside trending news and stock performance. The article appears to be primarily an aggregation of financial information rather than an in-depth analysis of the Form 4.
Form 4 Kymera Therapeutics Inc For: 1 October By Investing.com
This article announces the filing of a Form 4 for Kymera Therapeutics Inc. on October 1st. It also lists various financial market data, including indices, commodities, and shares, and trending stocks. The main content of the article is simply the title repeated with a stock symbol and the date.
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells 30,000 Shares of Company Stock
Kymera Therapeutics CEO Nello Mainolfi recently sold 30,000 shares of company stock for approximately $3.41 million, reducing his ownership by 4.31%. Despite this insider selling, the company reported stronger-than-expected quarterly results with revenue up 465.2% year-over-year. Analysts maintain a "Moderate Buy" consensus rating for KYMR with an average price target of $133.21.
Kymera Therapeutics CEO Nello Mainolfi sells $3.4 million in stock By Investing.com
Kymera Therapeutics CEO Nello Mainolfi sold approximately $3.4 million worth of common stock on October 1, 2026, after exercising stock options. These sales were conducted under a Rule 10b5-1 trading plan, following a significant 101% surge in Kymera's stock over the past year. Mainolfi now directly holds 666,568 shares and 60,000 stock options in the company.
After exercising options at $2.08 a share, Kymera Therapeutics (KYMR) CEO sells 30,000 shares.
Kymera Therapeutics (KYMR) CEO Nello Mainolfi exercised options for 30,000 shares at $2.08 per share on October 1, 2026. Simultaneously, he sold all 30,000 common shares in six separate transactions, with weighted-average prices ranging from $111.44 to $116.12. These transactions were executed under a Rule 10b5-1 plan adopted on March 24, 2026.
Kymera Therapeutics stock reports 465.2 percent revenue growth
Kymera Therapeutics reported a significant 465.2% year-over-year revenue growth in Q2 2026, reaching USD 65.0 million, primarily driven by collaboration income. The company also beat analyst estimates for adjusted loss per share. Stifel Nicolaus raised its price target for Kymera to USD 152.00, maintaining a Buy rating, highlighting the company's platform in targeted protein degradation and oral medicines for inflammatory diseases.
B.Riley reiterates Kymera Therapeutics stock rating on new trial data
B.Riley has reiterated a Buy rating and a $155.00 price target for Kymera Therapeutics (NASDAQ: KYMR) after the company presented new data from its oral STAT6 degrader KT-621 at EADV’26. The stock has seen a 104% increase over the past year, reflecting strong investor interest. Several other analysts, including Stifel, BofA Securities, Guggenheim, and Piper Sandler, have also recently increased their price targets and maintained Buy or Overweight ratings, indicating broad positive sentiment driven by potential Phase 2b data for KT-621.
Goldman Sachs resumes Kymera Therapeutics stock coverage
Goldman Sachs has resumed coverage of Kymera Therapeutics (NASDAQ:KYMR) with an Early-Stage Biotech rating. The stock has seen a significant surge of 120% over the past year, reaching $115.47, though InvestingPro analysis suggests it is currently overvalued. Kymera Therapeutics is a clinical-stage biopharmaceutical company focusing on targeted protein degradation technology with multiple drugs in clinical trials, including collaborations with Sanofi and Gilead Sciences.
Goldman Sachs resumes Kymera Therapeutics stock coverage By Investing.com
Goldman Sachs has resumed coverage of Kymera Therapeutics (NASDAQ:KYMR) with an Early-Stage Biotech rating. The stock has seen a significant surge of 120% over the past year, though InvestingPro analysis indicates it may be overvalued. Kymera Therapeutics is a clinical-stage biopharmaceutical company focusing on developing oral small molecule degrader medicines for various diseases.
Piper Sandler reiterates Kymera Therapeutics stock rating at $140 By Investing.com
Piper Sandler has reiterated an Overweight rating for Kymera Therapeutics (NASDAQ: KYMR) with a $140 price target, ahead of crucial Phase 2 clinical trial data for its drug candidate KT-621 in atopic dermatitis expected in Q4. The stock has shown strong performance, up 140% over the past year, trading near its 52-week high. While analyst consensus is bullish, InvestingPro suggests the stock might be overvalued at current levels.
Kymera Therapeutics stock gains as Stifel lifts its target
Kymera Therapeutics (KYMR) stock gained as Stifel raised its price target by 29%, driven by the company's clinical-trial outlook, bringing its market value to $9.78 billion. While the higher target implies potential upside, InvestingPro data suggests the stock is overvalued relative to its fair-value estimate, and its negative P/E ratio indicates reliance on future clinical progress rather than current earnings. Investors are advised to focus on trial execution and operating figures for future performance indicators.
(KYMR) Volatility Zones as Tactical Triggers
This article analyzes Kymera Therapeutics Inc. (NASDAQ: KYMR), identifying a strong near-term sentiment with a potential mid-term neutrality shifting towards a long-term positive bias. The analysis highlights a 47.1:1 risk-reward setup and provides three distinct AI-generated trading strategies tailored for different risk profiles. It also offers a multi-timeframe signal analysis indicating support and resistance levels.
Kymera Therapeutics (NasdaqGM:KYMR) Stock Price
This article provides an overview of Kymera Therapeutics (NasdaqGM:KYMR) stock, including its performance, analyst valuations, and recent company updates. It highlights that the stock is currently undervalued according to analyst consensus and high targets, driven by advancements in its clinical milestones, particularly for its KT-621 program in immunology. The company's key financial details, product pipeline, and recent insider trading activities are also discussed.
BofA Securities Adjusts Kymera Therapeutics Price Target to $144 From $123
BofA Securities has raised its price target for Kymera Therapeutics (KYMR) to $144 from $123. The company currently holds an average rating of "buy" and a mean price target of $137.73 among analysts.
BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $144
BofA Securities has reiterated its Buy rating on Kymera Therapeutics (KYMR.US) and increased the price target to $144. This reflects a positive outlook from the firm regarding the company's future performance.
California State Teachers Retirement System Raises Stock Position in Kymera Therapeutics, Inc. $KYMR
California State Teachers Retirement System significantly increased its holdings in Kymera Therapeutics, Inc. during the second quarter, now owning 7.51% of the company. Despite the company remaining unprofitable, it reported strong revenue growth and beat analyst expectations for its adjusted loss per share. Wall Street analysts maintain a "Moderate Buy" rating for Kymera Therapeutics, although company insiders have sold a substantial amount of stock.
Squarepoint Ops LLC Raises Holdings in Kymera Therapeutics, Inc. $KYMR
Squarepoint Ops LLC significantly increased its stake in Kymera Therapeutics (NASDAQ:KYMR) by 657% in the second quarter. This move aligns with positive sentiment from other institutional investors and Wall Street analysts, who largely rate the stock as a "Buy" with an average target price higher than its current trading price. Despite strong institutional buying and better-than-expected quarterly results, the article notes substantial insider selling totaling $386.9 million over the past 90 days.
Fund giant T. Rowe Price holds a double-digit stake in Kymera (KYMR)
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a 10.7% beneficial ownership stake in Kymera Therapeutics, Inc. (KYMR), totaling 8,873,588 shares as of August 31, 2026. The filing indicates T. Rowe Price holds sole voting power over 8,821,580 shares and sole dispositive power over all 8,873,588 shares, explicitly denying beneficial ownership to avoid legal construction of the filing as an admission. This disclosure provides transparency regarding significant institutional holdings in Kymera.
Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace
Kymera Therapeutics presented at the Wells Fargo 21st Annual Healthcare Conference, highlighting the accelerated progress of its oral immunology pipeline. The company announced an earlier data readout for its lead atopic dermatitis study (BROADEN2) by the end of 2026 and discussed promising early safety and efficacy signals for KT-621, an oral STAT6 degrader. Kymera aims to build a commercial global biopharma company focused on effective oral drugs for type 2 inflammation and autoimmune diseases, with additional programs like BREATH (asthma) and KT-579 (IRF5 degrader) also advancing.
Have Kymera Therapeutics Insiders Been Selling Stock?
Kymera Therapeutics (NASDAQ:KYMR) recently saw its Chief Legal Officer & Corporate Secretary sell US$744k worth of stock, an 11% reduction in their holding. Over the last year, the Chief Financial Officer also sold US$1.1m in shares. Despite high insider ownership of 1.2% (US$118m), the pattern of selling without corresponding purchases raises some caution for potential investors.
36,237 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Legal & General Group Plc
Legal & General Group Plc recently acquired 36,237 shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) worth approximately $4.16 million during the second quarter. This move aligns with other institutional investors, including BlackRock and Merck, establishing new positions in the company. Despite insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $128.70, following strong quarterly results where Kymera exceeded revenue and earnings per share expectations.
Kymera Therapeutics (NASDAQ:KYMR) Insider Brian Adams Sells 6,371 Shares of Stock
Kymera Therapeutics insider Brian Adams sold 6,371 shares of the company's stock for approximately $744,324 to cover tax withholding obligations. This sale reduced his holdings by 11.25% to 50,254 shares. The company's stock rose 0.1% to $117.39, with a market cap of $9.76 billion, and beat earnings and revenue expectations in its last quarter.
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock
Brian Adams, Kymera Therapeutics' Chief Legal Officer, disposed of approximately $744,297 worth of KYMR stock on September 4, 2026, to cover tax withholding obligations related to restricted stock units. Following these automatic transactions, Adams directly owns 50,254 shares. The company recently reported strong Q2 2026 revenues and has received optimistic price target adjustments from analysts like Guggenheim and Oppenheimer, though InvestingPro suggests the stock may be overvalued.
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock
Kymera Therapeutics' Chief Legal Officer, Brian Adams, sold approximately $744,297 worth of KYMR common stock to cover tax withholding obligations related to restricted stock units. This occurred on September 4, 2026, and was an automatic transaction. The company's stock has seen significant returns over the past year, though it is considered overvalued by some analyses, and recent financial results showed a revenue surge and positive analyst outlooks.
Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR
Atlas Venture Life Science Advisors LLC significantly reduced its stake in Kymera Therapeutics, Inc. by 37.8% in the second quarter, selling 1.73 million shares. Despite this, Kymera remains Atlas Venture's largest holding, and analysts maintain a "Moderate Buy" rating with an average price target of $128.70. The company reported strong Q2 earnings, exceeding revenue and EPS estimates, although company insiders sold a substantial amount of stock during the quarter.
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Kymera Therapeutics, Inc. $KYMR
UBS Asset Management Americas LLC reduced its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 15.9% in the second quarter, selling 139,006 shares and retaining 736,866 shares valued at $84.5 million. This comes as Kymera Therapeutics reported a significant 465.2% year-over-year revenue increase to $65 million and beat EPS estimates, though company insiders sold a substantial amount of shares. Analyst sentiment remains largely positive with a "Moderate Buy" rating and an average price target of $128.70.
Braidwell LP Buys 40,604 Shares of Kymera Therapeutics, Inc. $KYMR
Braidwell LP increased its stake in Kymera Therapeutics (NASDAQ:KYMR) by 12% in the second quarter, acquiring 40,604 additional shares to reach a total of 378,163 shares valued at approximately $43.4 million. Analysts maintain a "Moderate Buy" rating for the stock with an average price target of $128.70, while the company reported better-than-expected quarterly earnings despite significant insider selling.
21,058 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Jupiter Topco LLC
Jupiter Topco LLC recently acquired 21,058 shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) valued at approximately $2.4 million, reflecting increased institutional interest. Despite significant insider selling totaling $386.2 million over the past 90 days, analysts maintain a "Moderate Buy" rating with an average price target of $128.70, following a strong earnings report where Kymera beat EPS expectations and saw revenue surge by 465.2% year over year. The company's stock currently trades at $118.63, with a market capitalization of $9.86 billion.
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Kymera Therapeutics, a clinical-stage biopharmaceutical company focused on immunological diseases, announced its participation in several investor conferences in September. The company will present at events hosted by Wells Fargo, Citi, H.C. Wainwright, Morgan Stanley, and Stifel, offering webcasts and replays for investors. Kymera is pioneering targeted protein degradation to develop new oral small molecule degrader medicines.
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Kymera Therapeutics (KYMR) shares have risen 10.2% since its last earnings report, outperforming the S&P 500, following strong Q2 2026 results where revenues surged due to collaboration agreements with Gilead and Sanofi. Despite this, analysts' estimates have trended downward, leading to a Zacks Rank #3 (Hold) rating, suggesting an in-line return for the stock in the coming months. The company's R&D spending increased, but management expects its cash runway to fund operations through 2029.
Man Group plc Makes New $2.19 Million Investment in Kymera Therapeutics, Inc. $KYMR
Man Group plc initiated a new investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR), purchasing 19,085 shares valued at approximately $2.19 million during the second quarter. This move aligns with increased positions from other major institutional investors like BlackRock and Vanguard, reflecting broader investor confidence despite significant insider selling totaling $386.2 million in the same period. Analysts maintain a "Moderate Buy" consensus with an average price target of $128.70, further supported by the company's strong Q2 financial results, which included beating EPS estimates and a 465.2% year-over-year revenue increase.
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
Kymera Therapeutics (NASDAQ: KYMR) announced it will present data on its oral STAT6 degrader, KT-621, at upcoming European Respiratory Society (ERS) and European Academy of Dermatology & Venereology (EADV) Congresses in September 2026. The presentations will highlight previously reported data from the Phase 1b BroADen trial in moderate to severe atopic dermatitis, focusing on patients with comorbid asthma or allergic rhinitis, and on pruritus and sleep outcomes. KT-621 is currently in parallel Phase 2b trials for atopic dermatitis and asthma, with topline data for AD expected by year-end 2026 and for asthma in late 2027.
215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp
Bank of New York Mellon Corp has acquired 215,588 shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR), valued at approximately $24.7 million, representing about 0.26% of the company. Kymera Therapeutics beat quarterly earnings expectations with an adjusted loss of $0.62 per share and a significant revenue increase, although insiders have sold a substantial amount of stock recently. Analysts generally maintain a "Moderate Buy" rating for KYMR with an average target price of $127.17.
Kymera Therapeutics, Inc. $KYMR Shares Sold by Alyeska Investment Group L.P.
Alyeska Investment Group L.P. reduced its stake in Kymera Therapeutics (NASDAQ:KYMR) by 19.3% in the second quarter, selling 66,243 shares and retaining 276,455 shares valued at $31.7 million. Despite this sale, other major institutions like Baker BROS. Advisors, Avoro Capital, Vanguard, and T. Rowe Price increased their positions, and BlackRock initiated a significant stake. Kymera Therapeutics reported stronger-than-expected quarterly results with a smaller loss per share and a substantial 465.2% year-over-year revenue increase, leading analysts to maintain a "Moderate Buy" rating with a target price of $127.17.
Kymera Therapeutics (NASDAQ:KYMR) Gains on Higher Price Target
Kymera Therapeutics (NASDAQ:KYMR) is experiencing renewed investor interest and a higher price target due to strong quarterly revenue growth, a narrowed loss, and promising advancements in its targeted protein degradation pipeline. The company's unique approach to drug development, which aims to selectively remove disease-causing proteins, is viewed as a significant differentiator in the biotechnology sector. Future clinical milestones and effective financial management will be crucial for sustaining this positive momentum and realizing the commercial potential of its therapies.
Wellington Management Group LLP Trims Holdings in Kymera Therapeutics, Inc. $KYMR
Wellington Management Group LLP reduced its stake in Kymera Therapeutics, Inc. by 5.5% in the second quarter, selling over 214,000 shares but still maintaining a significant 4.42% ownership valued at $421.4 million. Despite this trimming and substantial insider selling, analysts generally hold a "Moderate Buy" rating for Kymera, which reported stronger-than-expected quarterly results with revenue up 465.2% year-over-year. The article also notes other institutional investors increasing their holdings and provides company financial performance and analyst target prices.
119,503 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company acquired 119,503 shares of Kymera Therapeutics (NASDAQ: KYMR) worth approximately $13.7 million in the second quarter of 2026. This acquisition, representing about 0.14% of the company, comes as other institutional investors also increased their holdings, despite significant insider selling. Kymera Therapeutics reported better-than-expected quarterly earnings and revenue, maintaining a "Moderate Buy" consensus rating from analysts with an average target price of $127.17.
20,000 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Bamco Inc. NY
Bamco Inc. NY acquired 20,000 shares of Kymera Therapeutics (NASDAQ:KYMR) in the second quarter, valued at approximately $2.3 million. This purchase is part of a trend of institutional investors increasing their positions, despite recent insider sales totaling about $386.2 million. Analysts maintain a "Moderate Buy" rating for Kymera, with an average price target of $127.17, following better-than-expected quarterly results.
Proficio Capital Partners LLC Invests $1.27 Million in Kymera Therapeutics, Inc. $KYMR
Proficio Capital Partners LLC recently invested $1.27 million in Kymera Therapeutics, Inc. (NASDAQ: KYMR) by acquiring 11,045 shares during the second quarter. This move aligns with increased institutional holdings from firms like Baker Bros. Advisors and Vanguard, as Kymera Therapeutics reported stronger-than-expected quarterly results. Despite significant insider selling and a negative net margin, analysts maintain a "Moderate Buy" consensus rating for the company.
Kymera Therapeutics, Inc. $KYMR Stock Holdings Increased by Odyssean LLC
Odyssean LLC significantly increased its stake in Kymera Therapeutics (NASDAQ:KYMR) by 132.7% in the second quarter, bringing its total holdings to 34,485 shares. This increase comes as Kymera Therapeutics reported better-than-expected quarterly results, with a smaller loss per share and a substantial 465.2% year-over-year revenue surge. Despite positive analyst ratings and a "Moderate Buy" consensus, the company saw significant insider selling totaling approximately $386.2 million during the same period.
Nicholas Investment Partners LP Invests $6.26 Million in Kymera Therapeutics, Inc. $KYMR
Nicholas Investment Partners LP has acquired a new stake worth $6.26 million in Kymera Therapeutics, Inc. Other institutional investors like BlackRock and Baker Bros. Advisors have also increased their positions, indicating positive sentiment despite significant insider selling. Analysts maintain a "Moderate Buy" consensus with an average price target of $125.65 for Kymera Therapeutics.
Nan Fung Group Holdings Ltd Invests $3.54 Billion in Kymera Therapeutics, Inc. $KYMR
Nan Fung Group Holdings Ltd recently acquired 30,875 shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) for approximately $3.54 billion during the second quarter, making it their 11th largest holding. Kymera Therapeutics reported strong quarterly revenue growth of 465.2% year-over-year, beating analyst estimates, and a narrower-than-expected loss per share. Despite significant insider selling in the last quarter, analysts maintain a "Moderate Buy" rating with a consensus price target of $125.65.
12,083 Shares in Kymera Therapeutics, Inc. $KYMR Bought by B. Metzler seel. Sohn & Co. AG
B. Metzler seel. Sohn & Co. AG recently acquired 12,083 shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the second quarter, valuing their new stake at approximately $1.386 million. This purchase is part of broader institutional interest, with several other firms increasing their holdings in the company. Kymera Therapeutics reported strong Q2 earnings, beating analyst expectations for both EPS and revenue, and analysts currently maintain a "Moderate Buy" consensus rating for the stock.
5,538,210 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by BlackRock Inc.
BlackRock Inc. recently acquired 5,538,210 shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR), valued at approximately $635.1 million, giving it a 6.73% stake in the company. Kymera Therapeutics reported strong quarterly revenue growth of 465.2% year-over-year, beating analyst expectations for both revenue and EPS, despite significant insider stock sales during the quarter. Analysts maintain a "Moderate Buy" rating with a consensus price target of $125.65.
Deutsche Bank AG Makes New $12.16 Million Investment in Kymera Therapeutics, Inc. $KYMR
Deutsche Bank AG has made a new investment of $12.16 million in Kymera Therapeutics, Inc. by purchasing 106,049 shares during the second quarter. This move makes Deutsche Bank AG the owner of approximately 0.13% of Kymera Therapeutics' stock. Several other institutional investors have also adjusted their positions in the company, while some insiders have sold shares.
